Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acenocoumarol (Novartis)
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Acenocoumarol (also known as acenocoumarin) is a coumarin-derived oral anticoagulant that acts as a vitamin K antagonist. It is widely used in Europe, India, and other regions for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis, pulmonary embolism, and stroke in patients with atrial fibrillation or mechanical heart valves. Acenocoumarol works by inhibiting the enzyme vitamin K epoxide reductase (VKOR), which prevents the reduction of vitamin K epoxide to its active hydroquinone form. This depletion of active vitamin K impairs the gamma-carboxylation and activation of vitamin K-dependent clotting factors II, VII, IX, and X, as well as anticoagulant proteins C and S. Compared to warfarin, acenocoumarol has a shorter elimination half-life, which can lead to a more rapid onset and offset of action, though it still requires careful monitoring of the International Normalized Ratio (INR) due to its narrow therapeutic index and susceptibility to genetic variations in CYP2C9 and VKORC1.
- Brand names
- AcebronAcitromAzecarCoarolFortonolIsqueliumMini-SintromNeo-SintromNistromSaxiomSin 4Sin4Sin-4SinkumSinkum 4Sinkum4Sinkum-4SinkumarSinthromeSintromSyncoumarSyncumarSynthrom
- Other names
- acenocoumarinacenocoumarolacenocumarolacenocumaroloacenokumarinnicoumalonenicumalonnitrovarfariannitrowarfarin
02
Targets
VKORC1 (Vitamin K epoxide reductase complex subunit 1)
Beyond the preview
Go deeper on acenocoumarol (Novartis).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acenocoumarol (Novartis).